---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-070732"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:19:12.830916+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma receives $475M milestone from Pfizer on Zavzpret approval, raises 2023 guidance

## Summary
- Received $475M accelerated milestone payment from Pfizer following FDA approval of Zavzpret (zavegepant) for acute migraine.
- Raised full-year 2023 Adjusted Cash Receipts guidance to $2,850M-$2,950M from prior $2,375M-$2,475M.
- Royalty Pharma will now earn royalties on net sales of both Nurtec ODT and Zavzpret.
- CEO Pablo Legorreta noted the milestone provides additional capital for redeployment to create long-term shareholder value.
- Guidance excludes contributions from future transactions and assumes no major unforeseen adverse events.

## SEC filing metadata
- accession: 0001193125-23-070732
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312523070732/0001193125-23-070732-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312523070732/d398207d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-070732
- JSON: https://secwatch.observer/filing/0001193125-23-070732.json
- Plain text: https://secwatch.observer/filing/0001193125-23-070732.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.